TV News LIES

Access to maternity care is decreasing in the parts of the U.S. that need it the most, affecting nearly 7 million women of childbearing age and some 500,000 babies.

That's according to a report released Tuesday by March of Dimes, a nonprofit focused on maternal and infant health. It finds that 36% of counties nationwide — largely in the Midwest and South — constitute "maternity care deserts," meaning they have no obstetric hospitals or birth centers and no obstetric providers.

It paints a slightly grimmer picture than the organization's last such report, which was released in 2020. Five percent of counties have a worse designation this time around, and there's been a 2% increase in counties classified as maternity care deserts — accounting for some 15,933 women living in more than 1,000 counties.

March of Dimes says these changes are driven primarily by the loss of obstetric providers and hospital services within counties, as a result of financial and logistical challenges including the COVID pandemic.

More...

On September 22 of last year, Michel Goldman, a Belgian immunologist and one of Europe’s best-known champions of medical research, walked into a clinic near his house, rolled up his sleeve, and had a booster shot delivered to his arm. He knew he’d need it more than most.

Just a few weeks earlier, Michel, 67, had been to see his younger brother, Serge, the head of nuclear medicine at the hospital of the Université Libre de Bruxelles, where both men are professors. Michel was having night sweats, and he could feel swollen lymph nodes in his neck, so his brother brought him in for a full-body CT scan. When the images came through to Serge’s computer they revealed a smattering of inky spots, bunched near Michel’s left armpit and running up along his neck. It was cancer of the immune system—lymphoma.

A Montana judge blocked health officials on Thursday from enforcing a state rule that would prevent transgender people from changing the gender on their birth certificate.

The U.S. Centers for Disease Control and Prevention said it will prioritize its public health response in a revamp of its structure after months of criticism over its handling of the COVID-19 and monkeypox pandemics.

A briefing document provided by the agency on Wednesday said an external report into its response found public guidance had caused confusion, while important information were sometimes released too late to inform federal decisions.

CDC Director Rochelle Walensky said in response the agency was undertaking a series of changes designed to make it more nimble at responding, quicker at providing data and less focused on publishing fully vetted scientific papers.

More...

A federal judge on Monday ruled in favor of three major U.S. drug distributors in a landmark lawsuit that accused them of causing a health crisis by distributing 81 million pills over eight years in one West Virginia county ravaged by opioid addiction.

The verdict came nearly a year after closing arguments in a bench trial in the lawsuit filed by Cabell County and the city of Huntington against AmerisourceBergen Drug Co., Cardinal Health Inc. and McKesson Corp.

"The opioid crisis has taken a considerable toll on the citizens of Cabell County and the City of Huntington. And while there is a natural tendency to assign blame in such cases, they must be decided not based on sympathy, but on the facts and the law," U.S. District Judge David Faber wrote in the 184-page ruling. "In view of the court's findings and conclusions, the court finds that judgment should be entered in defendants' favor."

More...

The Biden administration has gone all in on the COVID-19 antiviral Paxlovid, announcing new measures to make the oral treatment more widely available and making it clear that Vice President Harris used it as she recovered from the coronavirus.

The White House has said it will nearly double the amount of Paxlovid available around the country and that it is working to set up more Test-to-Treat locations in pharmacies and other locations.

But the administration faces a number of obstacles in really making Paxlovid, and a similar treatment from Merck and Ridgeback known as molnupiravir, easily accessible to Americans.

More...